Literature DB >> 30536809

Incidence, severity, longitudinal trends and predictors of acute and chronic oxaliplatin-induced peripheral neuropathy in Taiwanese patients with colorectal cancer.

Shu-Yi Hsu1, Wen-Shih Huang2, Shu-Hui Lee3, Tsui-Ping Chu4, Yung-Chang Lin5, Chang-Hsien Lu6, Randal D Beaton7, Sui-Whi Jane5,8.   

Abstract

The purpose of this study was to evaluate the longitudinal incidence, severity, pattern of changes or predictors of oxaliplatin-induced peripheral neuropathy (OXAIPN) in Taiwanese patients with colorectal cancer. A longitudinal repeated measures study design was employed, and 77 participants were recruited from the colorectal and oncology departments of two teaching medical centres in Taiwan. Physical examinations were performed, and self-reports regarding adverse impacts of OXAIPN and quality of life were obtained at five time points throughout 12 cycles of chemotherapy (C/T). The incidence of OXAIPN increased with C/T cycles (31.1%-81.9%), and the upper limb numbness and cold sensitivity were most significant acute OXAIPN symptoms (29.9%-73.6%). Findings also documented significant increases in overall severity, symptom distress, interference and physical results associated with OXAIPN over the course of C/T. Predictors of OXAIPN severity varied by treatment cycle, including younger patient, higher cumulative dose of oxaliplatin, greater body surface area, receipt of chemotherapy in winter and the occurrence of OXAIPN during prior C/T cycles. The results from this study might help healthcare providers to recognise the symptom characteristics, degree of influences, trends and high-risk group of OXAIPN, facilitating early evaluation and potential interventions to mitigate or prevent negative effects of OXAIPN on patients.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  Taiwanese patients with colorectal cancer; oxaliplatin-induced peripheral neuropathy; quality of life; symptom interference

Mesh:

Substances:

Year:  2018        PMID: 30536809     DOI: 10.1111/ecc.12976

Source DB:  PubMed          Journal:  Eur J Cancer Care (Engl)        ISSN: 0961-5423            Impact factor:   2.520


  4 in total

Review 1.  Platinum-induced peripheral neurotoxicity: From pathogenesis to treatment.

Authors:  Nathan P Staff; Guido Cavaletti; Badrul Islam; Maryam Lustberg; Dimitri Psimaras; Stefano Tamburin
Journal:  J Peripher Nerv Syst       Date:  2019-10       Impact factor: 3.494

2.  Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy.

Authors:  David Mizrahi; Susanna B Park; Tiffany Li; Hannah C Timmins; Terry Trinh; Kimberley Au; Eva Battaglini; David Wyld; Robert D Henderson; Peter Grimison; Helen Ke; Peter Geelan-Small; Julie Marker; Brian Wall; David Goldstein
Journal:  JAMA Netw Open       Date:  2021-02-01

3.  Predictors for development of oxaliplatin-induced peripheral neuropathy in cancer patients as determined by ordered logistic regression analysis.

Authors:  Yuko Kanbayashi; Takeshi Ishikawa; Yoshiaki Kuriu; Eigo Otsuji; Koichi Takayama
Journal:  PLoS One       Date:  2022-09-29       Impact factor: 3.752

4.  Impact of Chemotherapy-Induced Peripheral Neuropathy on Quality of Life in Patients with Advanced Lung Cancer Receiving Platinum-Based Chemotherapy.

Authors:  Hsing-Wei Hung; Chien-Ying Liu; Hsiu-Fang Chen; Chun-Chu Chang; Shu-Ching Chen
Journal:  Int J Environ Res Public Health       Date:  2021-05-26       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.